About the Company
We do not have any company description for Instil Bio, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Instil Bio, Inc.
Here’s Why Instil Bio (TIL) Declined in Q4 - Yahoo Finance
Headquartered in Dallas, Texas, Instil Bio, Inc. (NASDAQ:TIL) is a clinical-stage biopharmaceutical company. On March 21, 2023, Instil Bio, Inc. (NASDAQ:TIL) stock closed at $0.6460 per share.
Instil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the company
NasdaqCM:TIL 1 Year Share Price vs Fair Value Explore Instil Bio's Fair Values from the Community and select yours ...
Instil Bio Reports First Quarter 2024 Financial Results and Provides ...
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. Instil seeks to in-license/acquire and develop novel therapeutic candidates in ...
Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc ... - Nasdaq
Shares of Instil Bio, Inc. Have increased 72.33% over the past quarter, and have gained 180.49% in the last year. In comparison, the S&P 500 has only moved 2.37% and 14.4%, respectively.
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement ...
Instil’s lead asset, IMM2510, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. For more information visit www ...
Instil Bio, Inc. (TIL) latest press releases and corporate news ...
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD- (L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in ...
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?
May 29, 2025 — 12:00 pm EDT Written by Zacks Equity Research for Zacks -> Instil Bio, Inc. (TIL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy).
INSTIL BIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Instil ...
Instil Bio disclosed on October 31, 2022, that it had informed the FDA that it had voluntarily paused enrollment in a clinical trial due to problems in manufacturing one of its therapies.
Instil Bio Analyst Ratings and Price Targets | NASDAQ:TIL | Benzinga
Instil Bio Inc has a consensus price target of $72.29 based on the ratings of 10 analysts. The high is $180 issued by Baird on September 16, 2024.
Trade Instil Bio Inc Shares | Instil Bio Inc Share Price | Instil Bio ...
Instil Bio Inc chart This market's chart. This is a visual representation of the price action in the market, over a certain period of time. You can use this to help gauge a market’s performance.
Was The Smart Money Right About Instil Bio, Inc. (TIL)?
Instil Bio, Inc. (NASDAQ:TIL) is not the least popular stock in this group but hedge fund interest is still below average. Our overall hedge fund sentiment score for TIL is 23.9.
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement ...
Contacts: Investor Relations: 1-972-499-3350 investorrelations@instilbio.com www.instilbio.com Source: Instil Bio 2024 GlobeNewswire, Inc.
Similar Companies
Loading the latest forecasts...